Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.63 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019583 | 0.94 | HSP90AA1 (0.57) | HSP90AB1HSP90AA1HSP90B1ROCK1SLC6A9 | |
| SCHEMBL13649863 | 0.93 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1HSP90B1ROCK1SLC6A9 | |
| SCHEMBL1019796 | 0.90 | HSP90AB1 (0.65) | HSP90AB1HSP90AA1HSP90B1ROCK1SLC6A9 | |
| Hydrochloric Acid SCHEMBL1638060 | 0.89 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1ROCK1SLC6A9 | |
| SCHEMBL1019460 | 0.88 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1HSP90B1ROCK1SLC6A9 | |
| SCHEMBL1018434 | 0.88 | HSP90AB1 (0.67) | HSP90AB1HSP90AA1HSP90B1ROCK1ROCK2 | |
| SCHEMBL1017906 | 0.86 | HSP90AA1 (0.65) | HSP90AB1HSP90AA1HSP90B1ROCK1ROCK2 | |
| SCHEMBL1019641 | 0.86 | HSP90AB1 (0.65) | HSP90AB1HSP90AA1HSP90B1ROCK1ROCK2 | |
| SCHEMBL1020564 | 0.85 | HSP90AA1 (0.71) | HSP90AB1HSP90AA1HSP90B1ROCK1ALK | |
| SCHEMBL1019008 | 0.84 | HSP90AB1 (0.63) | HSP90AB1HSP90AA1HSP90B1ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | claimed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | claimed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | claimed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | claimed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | claimed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | claimed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | HSP90AB1 2096/4885HSP90AA1 2662/4885HSP90B1 3472/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | HSP90AB1 3671/4885HSP90AA1 4129/4885HSP90B1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.